Trial · NCT03511105
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Baseline Adjusted Total Protein Concentration in Broncho-alveolar (BAL) Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | Baseline and at 26 hours post-first dose | Evaluable Population. | Milligrams per liter | MEDIAN |
| SECONDARY | Baseline Adjusted Total Cell Count of Neutrophils in BAL Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | Baseline and at 26 hours post-first dose | Evaluable Population. | 10^6 cells per milliliter | MEDIAN |
| SECONDARY | Baseline Adjusted Differential Cell Count of Neutrophils in BAL Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | Baseline and at 26 hours post-first dose | Evaluable Population. | Percentage of total cell count | MEDIAN |
| SECONDARY | Number of Participants Reporting Serious Adverse Events (SAEs) and Non-SAEs | Up to Day 9 (FU/EW) | All Subjects Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline Values for Clinical Chemistry Parameters | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | International units per liter | MEAN |
| SECONDARY | Change From Baseline Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Creatinine | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Micromoles per liter | MEAN |
| SECONDARY | Change From Baseline Values for Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN) | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Millimoles per liter | MEAN |
| SECONDARY | Change From Baseline Values for Clinical Chemistry Parameter-C Reactive Protein (CRP) | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Milligrams per liter | MEAN |
| SECONDARY | Change From Baseline Values for Clinical Chemistry Parameter-Total Protein | Baseline (Day -1) and at Day 2 and Day 9 | All Subjects Population. | Grams per liter | MEAN |
| SECONDARY | Change From Baseline Values for Hematology Parameters | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Giga cells per liter | MEAN |
| SECONDARY | Change From Baseline Values for Hematology Parameter: Hemoglobin | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Grams per liter | MEAN |
| SECONDARY | Change From Baseline Values for Hematology Parameters: Hematocrit and Reticulocytes | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Percentage of red blood cells in blood | MEAN |
| SECONDARY | Change From Baseline Values for Hematology Parameter: Mean Corpuscular Hemogloblin (MCH) | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Picograms | MEAN |
| SECONDARY | Change From Baseline Values for Hematology Parameter: Mean Corpuscular Volume (MCV) | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Femtoliters | MEAN |
| SECONDARY | Change From Baseline Values for Hematology Parameter: Red Blood Cell (RBC) Count | Baseline (Day -1)and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Tera cells per liter | MEAN |
| SECONDARY | Change From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | pH | MEAN |
| SECONDARY | Change From Baseline in Urine Specific Gravity | Baseline (Day -1) and at Day 2 and Day 9 (FU/EW) | All Subjects Population. | Ratio | MEAN |
| SECONDARY | Number of Participants With Worst Case Post Baseline Abnormal Electrocardiogram (ECG) Findings | Up to Day 9 (FU/EW) | All Subjects Population. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Findings During Physical Examinations | Up to Day 9 (FU/EW) | Safety Population. This analysis was not planned and data was not collected and captured in the database. | ||
| SECONDARY | Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | Baseline (Day -1) and at 1, 6, 12, 14, 30 hours and Day 9 (FU/EW) | All Subjects Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). | Millimeters of mercury | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03511105/outcomes